Human MxA protein suppresses mammalian H5N1 virus replication, but emerging mutations may enable partial evasion, raising ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug ...

Lenacapavir has shown high efficacy in managing multidrug-resistant cases offering hope to patients with limited alternatives A significant breakthrough in treating the Human Immunodeficiency Virus HI ...

In 2025, public health concerns focus on the threats of bird flu, malaria, HIV, and tuberculosis. H5N1 influenza poses a ...

Scientists are issuing warnings after a bird flu patient showed mutations that could increase the transmission of the virus.

This manuscript provides valuable information about the genesis of CPSF6 condensates due to HIV-1 infection. However, the evidence is incomplete as it is missing more functional assays. Furthermore, ...

The human immune deficiency virus (HIV) first entered public consciousness in the early 1980s, after cases of unfamiliar and deadly illnesses began to overwhelm medical centers across North America.

All three cases had a distinct genetic mutation that made the bacteria resistant to yet another class ... a 62-year-old man with a history of HIV/AIDS and hepatitis C, was ill enough to be ...

A rash may occur after you contract HIV. It commonly appears on the face and chest but can also appear in other places. Medications used to treat HIV as well as certain infections may also cause ...

Lenacapavir is already approved for use as a treatment for multi-drug resistant HIV, costing around $42,250 for the first year of therapy in the United States. Clinical trials this year showed it ...